Tarsus PharmaceuticalsTARS
TARS
About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Employees: 323
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
145% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 22
56% more capital invested
Capital invested by funds: $1.43B [Q3] → $2.23B (+$802M) [Q4]
18% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 55
18% more funds holding
Funds holding: 162 [Q3] → 191 (+29) [Q4]
13% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 9 (+1) [Q4]
8.78% less ownership
Funds ownership: 114.07% [Q3] → 105.29% (-8.78%) [Q4]
74% less call options, than puts
Call options by funds: $4.57M | Put options by funds: $17.5M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$58
17%
upside
Avg. target
$67
36%
upside
High target
$78
58%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 17%upside $58 | Buy Maintained | 6 Mar 2025 |
Guggenheim Eddie Hickman 33% 1-year accuracy 3 / 9 met price target | 58%upside $78 | Buy Maintained | 26 Feb 2025 |
HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 24 / 50 met price target | 48%upside $73 | Buy Reiterated | 26 Feb 2025 |
Barclays Balaji Prasad 16% 1-year accuracy 7 / 44 met price target | 21%upside $60 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
13 hours ago
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif.
Neutral
GlobeNewsWire
1 month ago
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Seeking Alpha
1 month ago
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects.
Neutral
GlobeNewsWire
1 month ago
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m. / 11:00 a.m. ET.
Neutral
Seeking Alpha
1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Negative
Zacks Investment Research
1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.
Neutral
GlobeNewsWire
2 months ago
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:
Positive
Zacks Investment Research
3 months ago
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Charts implemented using Lightweight Charts™